Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: An open labeled randomized controlled trial of lactulose versus no lactulose

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 8, 2012, Pages 1329-1335

  Sharma, Praveen ^a   Sharma, Barjesh Chander ^a   Agrawal, Amit ^a   Sarin, Shiv Kumar ^a  

^a G B PANT HOSPITAL   (India)

Author keywords

Cirrhosis; Hepatic encephalopathy; Lactulose; Primary prophylaxis

Indexed keywords

LACTULOSE;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CRITICAL FLICKER FUSION; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PREDICTION; PRIORITY JOURNAL; PROPHYLAXIS; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY;

EID: 84864296945     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2012.07186.x     Document Type: Article

References (28)

1. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: Final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35: 716-21.
2. Bustamante J, Rimola A, Ventura PJ etal. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J. Hepatol. 1999; 30: 890-5.
3. Romer Gómez M, Córdoba J, Jover R etal. Value of the critical flicker frequency in patients with minimal hepatic encephalopathy. Hepatology 2007; 45: 879-85.
4. Poordad FF. Review article: The burden of hepatic encephalopathy. Aliment. Pharmacol. Ther. 2007; 25 (Suppl. 1): 3-9.
5. Riordan SM, Williams R. Treatment of hepatic encephalopathy. N. Engl. J. Med. 1997; 337: 473-9.
6. Bajaj JS. Review article: The modern management of hepatic encephalopathy. Aliment. Pharmacol. Ther. 2010; 31: 537-47.
7. Blei AT, Co'rdoba J, for the Practice Parameters Committee of the American College of Gastroenterology. Hepatic encephalopathy. Am. J. Gastroenterol. 2001; 96: 1968-76.
8. Atterbury CE, Maddrey WC, Conn HO. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled, doubleblind clinical trial. Am. J. Dig. Dis. 1978; 23: 398-406.
9. Camma C, Fiorello F, Tine F, Marchesini G, Fabbri A, Pagliaro L. Lactitol in treatment of chronic hepatic encephalopathy. A meta-analysis. Dig. Dis. Sci. 1993; 38: 916-22.
10. Sharma BC, Sharma P, Agrawal A, Sarin SK. Secondary prophylaxis of hepatic encephalopathy: An open-label randomized controlled trial of lactulose versus placebo. Gastroenterology 2009; 137: 885-91.
11. Romero-Gomez M, Boza F, Garcia-Valdecasas MS, García E, Aguilar-Reina J. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am. J. Gastroenterol. 2001; 96: 2718-23.
12. Das A, Dhiman RK, Saraswat VA, Verma M, Naik SR. Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. J. Gastroenterol. Hepatol. 2001; 16: 531-5.
13. Hartmann IJ, Groeneweg M, Quero JC etal. The prognostic significance of subclinical hepatic encephalopathy. Am. J. Gastroenterol. 2000; 95: 2029-34.
14. Watanabe A, Sakai T, Sato S etal. Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy. Hepatology 1997; 26: 1410-14.
15. Sharma P, Sharma BC, Puri V, Sarin SK. An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. Eur. J. Gastroenterol. Hepatol. 2008; 20: 506-11.
16. Prasad S, Dhiman RK, Duseja A etal. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 2007; 45: 549-59.
17. Riggio O, Balducci G, Ariosto F etal. Lactitol in prevention of recurrent episodes of hepatic encephalopathy in cirrhotic patients with portal-systemic shunt. Dig. Dis. Sci. 1989; 34: 823-9.
18. Garcia-Tsao G, Friedman S, Iredale J, Pinzani M. Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. Hepatology 2010; 51: 1445-9.
19. Luo M, Li L, Lu CZ, Cao WK. Clinical efficacy and safety of lactulose for minimal hepatic encephalopathy: A meta-analysis. Eur. J. Gastroenterol. Hepatol. 2011; 23: 1250-7.
20. Ong JP, Aggarwal A, Krieger D etal. Correlation between ammonia levels and the severity of hepatic encephalopathy. Am. J. Med. 2003; 114: 188-93.
21. Shawcross DL, Davies NA, Williams R, Jalan R. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J. Hepatol. 2004; 40: 247-54.
22. Marini JC, Broussard SR. Hyperammonemia increases sensitivity to LPS. Mol. Genet. Metab. 2006; 88: 131-7.
23. Blei AT. Infection, inflammation and hepatic encephalopathy, synergism redefined. J. Hepatol. 2004; 40: 327-30.
24. Sharma P, Sharma BC, Puri V, Sarin SK. Critical flicker frequency: Diagnostic tool for minimal hepatic encephalopathy. J. Hepatol. 2007; 47: 67-73.
25. Kircheis G, Wettstein M, Timmermann L etal. Critical flicker frequency for quantification of low-grade hepatic encephalopathy. Hepatology 2002; 35: 357-66.
26. Sharma P, Sharma BC, Sarin SK. Critical flicker frequency for diagnosis and assessment of recovery from minimal hepatic encephalopathy in patients with cirrhosis. Hepatobiliary Pancreat. Dis. Int. 2010; 9: 27-32.
27. Bouhnik Y, Attar A, Joly FA etal. Lactulose ingestion increases faecal bifidobacterial counts: A randomised double-blind study in healthy humans. Eur. J. Clin. Nutr. 2004; 58: 462-6.
28. Mittal VV, Sharma BC, Sharma P, Sarin SK. A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. Eur. J. Gastroenterol. Hepatol. 2011; 23: 725-32.